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Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder 
predominately affecting the aging population. It is the second most common 
neurodegenerative disorder after Alzheimer’s disease (AD) affecting over 1 million 
individuals in the US alone. Recent studies have tried to understand the exact nature in 
which healthy neurons transition to a degenerative state in PD. There are a multitude of 
combinatory factors that can lead to the development of PD including environmental 
factors, genetic factors, and aging. The majority of PD cases are sporadic in nature, 
however familial cases account for 5-10% of total PD cases world-wide. The hallmark 
feature of PD is the formation of Lewy bodies, abnormal protein aggregates enriched in 
the protein -synuclein (a-syn) in dopaminergic neurons of the substantia nigra. These 
aggregates affect the overall protein homeostasis (proteostasis) in neurons causing 
deleterious effects. The lack of accurate diagnostic biomarkers clearly represents a 
challenge for PD patients and their caregivers.  
It has become increasingly apparent that microRNAs (miRNA), key regulators of 
gene expression, are involved in numerous disease processes including PD. We 
investigated miR-335-5p and miR-3613-3p, two microRNAs previously reported by our 
laboratory, to be significantly up-regulated in serum samples of PD patients as compared 
to healthy age-matched controls. We also corroborated those findings when we extracted 
 
 
RNA from frontal cortex tissue of PD patients and age-matched controls finding that 
miR-335-5p, miR-3613-3p, and miR-6865-3p were all significantly upregulated in 
patients with PD. Using mass spectrometry and in silico prediction methods we identified 
a number of potential protein targets for both miR-335-5p and miR-3613-3p. Using 
several molecular approaches, we found that three proteins involved in PD pathogenesis 
are regulated by miR-335-5p and miR-3613-3p, respectively. Ataxin-3 (ATXN3), BCL2 
Associated athanogene 5 (BAG5), and Autophagy related 5 (ATG5) are all proteins 
targeted and regulated by both miR-335-5p and miR-3613-3p. miR-335-5p and miR-
3613-3p have not previously been characterized for their potential biological roles with 
respect to neurodegeneration or neuroprotection. In this study we further dissect the 
neuroprotective role of both miR-335-5p and miR-3613-3p  in cells induced with stress. 
Our results significantly contribute to our understanding of PD and the contributing 
factors to neurodegeneration.  
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1.1. Parkinson’s Disease 
 
 
Neurodegenerative disorders such as Parkinson’s disease (PD), Alzheimer’s disease 
(AD), Huntington’s disease (HD), and Amyotrophic lateral sclerosis (ALS) are all caused 
by neuronal dysfunction and cell death. Neurodegeneration is a complex process often 
influenced by a combination of genetic, molecular, and environmental factors [1]. PD is 
an irreversible and slow progressing disorder involving both motor and non-motor 
symptoms such as sleep disorders, loss of smell, depression, and skin problems [2]. PD is 
the second most common neurodegenerative disorder associated, with selective 
degeneration of dopamine-producing neurons in the substantia nigra pars compacta 
(SNpc) [3]. The appearance of Lewy Bodies (LB) is a pathological hallmark of the 
disease and was first discovered by Frederic Lewy in 1912. These LBs are abnormal 
aggregation of proteins mainly alpha-synuclein (-syn), that cause an array of issues for 
neuronal cells, ultimately leading to cell death [4]. PD affects over 5 million individuals 
worldwide, and over 1% of the US population over the age of 60. This number is grossly 











PD is characterized by both motor and non-motor symptoms, but most individuals are 
diagnosed when characteristic motor symptoms appear. It has been shown that by the 
time motor symptoms occur, 60-80% of dopaminergic neurons have already been 
compromised severely limiting treatment options [5]. Parkinsonism is a syndrome 
characterized by tremor, bradykinesia, rigidity, and postural instability [6]. These four 
cardinal signs are what physicians currently use to diagnose patients with suspected PD 
along with the clinical history of the patient and a possible DaTSCAN.  
Tremor is the most common and well-known symptom of the four major motor 
symptoms. Tremor is defined as a rhythmical, involuntary oscillatory movement of a 
body part [7]. Resting tremor is developed at the onset of the disease and worsens as PD 
progresses [8]. Making an accurate diagnosis of tremor disorders is challenging, since 
similar disorders such as essential tremor (ET) and dystonic tremor can all cause 
misdiagnosis [9]. Tremors are more common in arms compared to legs and the frequency 
of these tremors is usually 4-6 hertz [10].  
Bradykinesia is characterized by reduction in spontaneous movements giving an 
appearance of stiffness. This stiffness and reduction in movement affects a patients 
ability to perform daily tasks such as writing, brushing teeth, and getting dressed [10]. 
There are a range of issues that are related to bradykinesia, however in most cases the 
principal deficit is that movements are slow. Several factors contribute to bradykinesia 
such as muscle weakness, tremor, rigidity, and the primary factor is due to insufficient 
recruitment of muscle force during initiation of movement, this results in patients’ 




Rigidity is a hypertonic state characterized by constant resistance throughout 
range of motion that is independent of velocity [12]. Rigidity is one of the physician’s 
telltale sign that helps them diagnose PD. It is caused by loss in muscle tone accompanied 
by extreme stiffness [8]. Further, rigidity is often asymmetric but affects the entire body 
as the disease progresses. This can lead to problems with achiness or pain in the muscles 
or joints affected. Many people with PD will have reduced arm swing when walking, 
more so on the most affected side. It has also been shown that rigidity negatively impacts 
sleep quality due to pain making it hard to fall or stay asleep [13].  
Postural instability refers to imbalance and loss of ability to stand upright. This 
loss of reflex and imbalance leads to frequent falls, which may cause bone fractures [8]. 
Postural instability has been identified as a feature of late-stage PD, and considered one 
of the most important criteria for diagnosing and categorizing PD patients [14]. These 
motor impairments are caused by dopaminergic neuronal deficits [15]. One study found 
that about 38% of patients experience falls due to instability and the frequency of falls 
increases with severity of the disease [16]. These falls are the most common reason for 
emergency room visits and largest motor related contributor to health care costs in PD 
patients [17].  
There are also some non-motor symptoms associated with PD, which include 
sleep disorders, psychosis, dementia, depression, hallucinations, and mood disorders to 
name a few [8]. Gastrointestinal (GI) issues such as constipation and excessive saliva, as 
well as loss of smell, are also observed in patients especially during the early stages of 
the disease, and usually antedate the first occurrence of motor signs [18]. In 2003, Braak 




initiation of sporadic PD [3]. Braak postulated that sporadic PD starts in two places: the 
neurons of the nasal cavity and the neurons in the gut causing the spread of -syn via the 
vagus nerve and olfactory bulb [19]. The Braak hypothesis has also received criticism 
due to the fact that not all PD patients follow the proposed staging system. The mean age 
of onset is 60, however some cases appear between the ages of 20-50 [10]. Some studies 
point to PD being more common in men as compared to women [20].  
 
 
1.3. Four factors influencing PD pathogenesis 
 
The exact cause for the onset of PD is still unknown, however there are many risk factors 
  
associated with developing PD. It is unlikely that a single factor contributes to PD, 
instead a multitude of factors such as age, genetics, environmental factors, and many 
molecular factors such as protein aggregation, autophagy, and mitochondrial dysfunction 
most probably act in concert.  
Age is usually one of the major factors when it comes to neurodegenerative 
diseases [21], and PD is characterized as an age-related disorder. The risk of developing 
idiopathic PD after the age of 60 increases dramatically. This age-related risk is due to a 
multitude of factors which include the inherent weakening of the neuronal cellular repaid 
system [22], as well as increased genetic mutations. Neuronal protein aggregation 
represents a hallmark of PD pathogenesis and proteosome dysfunction may contribute to 
the increased susceptibility of developing PD [23]. Mitochondrial dysfunction also 
increases with age and can lead to increased levels of reactive oxygen species (ROS) [24] 




Genetics also play an important role in both idiopathic and familial PD. Most PD 
cases are sporadic, however approximately 10% of cases are familial or genetic [25]. 
Mutations in genes such as Leucine-rich repeat kinase 2 (Lrrk2), PTEN-induced putative 
kinase 1 (PINK1), a-syn and Htra serine peptidase 2 (Park13) are all associated with PD 
onset and progression [26, 27]. Autosomal recessive forms of early-onset PD are caused 
by mutations in Parkin (PARK2) [28], and PTEN-induced putative kinase 1 (PINK1) 
[29], both Parkin and PINK1 lead to mitochondrial dysfunction through the E3-ubiquitin 
ligase pathway [30]. Despite extensive studies the molecular and genetic pathways 
leading to the onset and progression of PD are poorly understood. 
Environmental factors have also been shown to have a causative role in the onset 
of PD. For example, paraquat (1’-dimethyl-4-4’-bypyridinium dichloride) has been 
associated with PD where subjects, usually farmers associated with this pesticide, have an 
increased risk of developing PD [31]. Paraquat causes an increase in ROS levels leading 
to increased oxidative stress in neurons [32]. Insecticides and Organochlorides, such as 
dieldrin, have also been shown to increase the risk of developing PD [33]. Interestingly, 
some studies have also suggested that metal toxicity is correlated with the risk of 
developing PD [34]. Indeed, one finding showed that postmortem PD brains had 
increased iron levels [34], and that this elevation could in turn cause an in increase in 
oxidative stress ultimately leading to cell death. Metal toxicity alone does not necessarily 
increase the risk of developing PD, however coupled with other contributing factors it 
may increase the occurrence of PD.  
Molecular factors contributing to the onset of PD include protein aggregation, 




However, as a high level summary all of these factors contribute to proteostasis 
dysfunction in cells. 
 
1.3.1. Protein Aggregation 
 
The aggregation of disease-specific proteins is a hallmark of many neurodegenerative 
disorders. The presence of pathological aggregates, often called bodies or inclusions, 
certainly classify both PD and AD. In most cases these pathological aggregates result 
from the accumulation of misfolded and damaged proteins. In PD, LBs are enriched in -
syn and this aggregation has been correlated with inappropriate protein misfolding, and 
protein accumulations. -syn proteotoxicity has traditionally be attributed to LB 
formation in neurons. However, more recent studies have emerged suggesting that 
smaller non-fibrillar, multimeric species of -syn are more significant to PD 
pathogenesis [35, 36]. These multimers interact with and damage cell membranes [37]. 
Inappropriate autophagy is also implicated in the abnormal protein accumulation and 
aggregation of proteins such as SNCA as cells age. Proteosome dysfunction is also 
responsible for accumulation of aggregated proteins such as a-syn due to its inability to 
clear misfolded proteins [38].  
 
1.3.2. Oxidative stress 
Oxidative stress is the major source of mitochondrial dysfunction, which is caused either 
by dysfunctioning mitochondria producing more ROS or the inabilty to sustain proper 
regulation of ROS [39]. The consequences of oxidative stress are overarching and 




elucidating the link between neurodegenerative diseases and age [39]. Oxidative stress 
can alter transcription and translation of disease proteins by reacting with transcription 
factors or altering enzymes respectively. Neurons combat oxidative stress by employing a 
battery of antioxidant proteins called Peroxiredoxins involved in regulating H2O2 levels 
[40]. Oxidative stress contributes to neuronal cell death in PD due to a gradual decrease 
of the cells ability to cope with cellular damage over time [41].  
Several key PD-associated proteins are linked to mitochondrial function and ROS 
regulation such as, PINK1, PARK13, Parkin, and -syn. PINK1 along with Parkin 
regulates mitophagy in response to mitochondrial dysfunction. PARK13, also activated 
by PINK1, is a protease, which removes damaged mitochondrial proteins [42]. PARK13 
mutations have been associated with oxidative stress and PD phenotypes, while 
overexpression and knockout mouse models have shown both neuroprotection and PD 
phenotypes [43, 44]. The accumulation of a-syn on the outer and inner membranes of 
mitochondria in dopaminergic neurons decrease mitochondria complex 1 activity and 
induced ROS levels [45]. Furthermore, mitochondria are fundamental regulators of 
apoptosis, which makes oxidative stress-induced mitochondrial dysfunction an important 




Autophagy is a cellular process that involves the efficient and selective degradation of 
misfolded/ aggregated proteins [47]. Autophagy is a lysosomal-mediated degradation 
pathway that is activated under stress conditions to degrade and eliminate damaged 




autophagy-related proteins (ATGs) that are responsible for autophagosome formation, 
vesicle expansion, infusion with the lysosome, and cargo recruitment [49]. A complex of 
protein kinases initiates the signaling mechanism that controls the activation of 
autophagy, one of which is the mammalian target of rapamycin (m TOR) [50]. Defects in 
autophagy are associated with the pathogenesis of many neurodegenerative diseases and 
controlled modifications of autophagy may prove very useful in the development of 
possible therapeutics [51]. Autophagy provides a clear link to PD and aging due to the 
decline in cells ability to properly remove misfolded and aggregated proteins [44]. The 
pathogenic mutations of -syn A30P and A53T have been shown to block the uptake of 
damaged proteins or substances by the lysosome [52]. This inhibition is one of the key 
aspects in the pathogenesis and progression of PD. It appears therefore that as neurons 
age the susceptibility to develop PD increases based on reduced autophagy and clearing 
of misfolded proteins such as SNCA. Indeed, mice deficient in the Autophagy-related 
proteins ATG5 and ATG7 show accumulation of ubiquitinated aggregated proteins 
causing neuronal stress and ultimately leading to cell death [53]. Another example is 
illustrated by mitochondrial dysfunction where enlarged mitochondria do not get 
removed by mitophagy [54]. The loss of function of mitophagy is caused by elevated 
ROS levels and decreased lysosomal-autophagic degradation resulting from mutations in 
DJ-1, a protein involved in cellular protection against oxidative stress [55]. Indeed, 
enlarged mitochondria are often observed in PD subjects, possibly resulting from the 
fusion of damaged mitochondria and compromised mitophagy [54]. This enlarged mass is 
not observed in healthy subjects which show a 30% decrease in mitochondrial mass [56]. 




recycling of unnecessary or dysfunctional components of the cell. This process needs to 
be tightly regulated by chaperones and proteins to maintain cellular homeostasis.  
 
1.4. Clinical significance 
 
Despite extensive research in the field the exact processes that contribute to the onset of 
PD is poorly understood. Similarly, there has been no test formulated to correctly 
diagnose PD. This presents a unique opportunity where combining research strategies 
such as cellular assays and miRNA technology may lead to the identification of new 
targets and pathways that could act as potential biomarkers for the identification of PD. 
There is no biochemical test available to accurately diagnose PD, and patients often have 
to visit multiple physicians and perform multiple tests to diagnose [57]. The most 
effective drug to treat PD symptoms is dopamine replacement with Levodopa (L-Dopa), 
which was discovered in the 1960s. This treatment is only effective for a short period of 
time and also has severe side effects such as motor dyskinesia and increased oxidative 
stress caused by metabolites of dopamine [58] . There is a great need to establish novel 
pathways for potential therapeutics and drug design, as well as the development of 




miRNAs are a class of non-coding RNAs, 22 nucleotides in length, that play important 
roles in gene regulation. Among all regulatory molecules, miRNAs are the most studied, 
particularly as regulators in human diseases [59]. Most miRNAs are transcribed from 




miRNAs (Pre-miRNAs) and mature miRNAs [60]. Pri-miRNAs are transcribed from 
miRNA-encoding genomic sequences by RNA polymerase II [61, 62], and they are then 
processed into pre-miRNAs by the microprocessor complex, consisting of and RNA 
binding protein DiGeorge syndrome critical region 8 (DGCR8) and ribonuclease III 
enzyme drosha [63]. Once pre-miRNAs are generated they are exported to the cytoplasm 
by exportin 5 and then processed by dicer [63]. This processing involves the removal of 
the terminal loop, resulting in a mature miRNA duplex [64]. The directionality of the 
miRNA strand determines the name of the mature miRNA strand. For instance, the 3p 
strand originates from the 3’ end and the 5p strand originates from the 5’ end of the pre-
miRNA hairpin [65]. miRNAs are proposed to be downregulators of gene expression via 
two mechanisms: A). mRNA cleavage and B). translational repression. Through mRNA 
cleavage the miRNA binds to complementary regions of protein-coding mRNA 
sequences resulting in RNA induced silencing complex (RISC) cleavage [66]. 
Alternatively, and in the absence of appropriate complementarity, miRNAs also have the 
ability to bind to 3’UTRs and block translation [66]. Intriguingly, miRNAs do not solely 
function as target-specific regulators but may play key roles in post-transcriptional 
reduction of expression [67].  
Many studies have noted circulating miRNAs in biological fluids such as plasma, 
serum, cerebrospinal fluid, saliva, and breast milk to name a few [68-71]. These 
extracellular miRNAs are highly stable resisting degradation at room temperature, high or 
low pH, and multiple freeze thaw cycles [72]. Extracellular miRNAs can be either found 
in vesicles such as exosomes and microvesicles [73] or associated with proteins such as 




to protect miRNAs and increase stability in extracellular fluid [70]. It is now accepted 
that extracellular circulating miRNAs can play important roles in intracellular 




A-syn is primarily expressed in neuronal tissues and is linked genetically and 
neuropathologically to PD. A neuropathological hallmark of PD is the presence of LB 
which are insoluble aggregates enriched in the a-syn protein [74]. The SNCA gene 
encodes for an 140 amino acid protein that does not have a defined structure and whose 
function is not fully understood. In 1997, SNCA became one of the first reported genetic 
aberration linked to PD [26]. The mutation corresponded to substitution in the SNCA, 
resulting in an A53T amino acid change in the a-syn protein [26]. The pattern of 
inheritance was autosomal-dominant and the disease was early-onset, generally around 
the age of 40. Soon after two more autosomal dominant pathogenic SNCA mutations were 
also discovered, A30P and E46K [75, 76]. In 2003, an SNCA triplication event was 
reported, resulting in a two-fold increase in a-syn protein levels, which could ultimately 
lead to development of PD [77].  
A-syn may contribute to PD in multiple ways but it is generally thought that its 
protofibrils are the toxic species that mediate disruption of the cellular homeostasis and 
neuronal death [78]. Furthermore, secreted a-syn may exert deleterious effects on 
neighboring cells including seeding of aggregation, possibly contributing to the 




important aspects of a-syn with respect to PD, it is still unclear how changes in SNCA/a-




Parkin is an E3 ubiquitin ligase which ubiquitinates mitochondrial proteins and targets 
them for proteasomal degradation [30]. Mutations in Parkin cause loss of E3 ligase 
function, and account for the second most common cause of PD [28]. Parkin plays an 
important role in Familial PD due to genetic defects in Parkin causing autosomal 
recessive PD. PINK1 acts upstream of Parkin and is required for Parkin activation and 
recruitment to depolarized mitochondria [80]. Parkin gets selectively recruited to 
damaged mitochondria and brings about ATG5-dependent mitophagy by recruiting 
ubiquitin and p62 to mitochondrial membrane [81]. Parkin overexpression acts as a 
protective agent reducing proteotoxicity in dopaminergic neurons [82]. 
Parkin has also been shown to prevent cell death through proteasomal degradation 
of certain aggregated proteins such as SNCA. The exact mechanism of how over 
expression protects against proteotoxicity is unknown, but it seems to be dependent on its 
E3 ligase activity [83]. Mitochondrial deficits are also very prevalent in Parkin deficient 
patients where decreased lymphocyte mitochondrial complex I is observed [84], and this 
has also been observed in Parkin-knockout mice which show oxidative stress and 
mitochondrial dysfunction [85]. Numerous mutations throughout the PRKN gene are 
linked to autosomal recessive PD which is associated with early-onset PD [86], making 







Autophagy is a highly conserved homeostatic process from yeast to mammals that 
involves degradation of certain intracellular molecules and organelles [87]. Autophagy is 
a tightly regulated process with 41 Autophagy-related proteins [88]. The autophagy 
pathway plays an important role in the pathological process of neurodegenerative 
diseases like PD. Autophagy related gene 5 (ATG5) plays an important role in initiation 
and vacuole formation in autophagy [89]. Knocking down ATG5 can result in 
downregulation or inhibition of autophagy suggesting that ATG5 plays an essential role 
in autophagy, and thus ATG5 is one of the most targeted genes in autophagy gene editing 
assays [90]. ATG5 initiates the formation of the autophagosome membrane and the 
fusion of autophagosomes and lysosomes functioning in both canonical and non-
canonical autophagy. ATG5 has been shown to play a protective role in neurons 
displaying synucleinopathies and ATG5 deficiencies led to deficits in motor function 
with accumulation of cytoplasmic inclusion bodies in the neurons of mice [91]. 
Autophagy is essential to the clearing of misfolded/aggregated proteins, therefore 
disruption in the initiation or any steps can lead to cell death. One finding displayed that 
ATG5 acted as a protective mechanism in zebrafish induced with the compound 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) a mitochondrial toxin [92]. MPTP is 
a standard compound used to establish PD models in vitro and in vivo causing damage to 
dopaminergic neurons [93]. ATG5 downregulation along with treatment impacted the 
progression of PD and PD-related markers, however when ATG5 was overexpressed it 




patients with PD, ATG5 protein levels were altered, which suggests that ATG5 may 




Post-translational modification of proteins is central to regulating stability and activity. 
One important modification involved in cellular homeostasis is ubiquitination which 
involves tagging proteins for degradation [95]. Ataxin-3 (ATXN3) is a deubiquitinating 
enzyme involved in protein quality control and is involved in removing ubiquitin from 
proteins prior to degradation so that the ubiquitin may be recycled [96]. It’s known 
activities include regulating the action of E3 ligases, participating in proteasomal 
substrate delivery, and regulating aggresome formation [97]. Mutations in SCA3, the gene 
encoding ataxin-3 causing repeat expansion causes spinocerebellar ataxia-3 (SCA3), the 
most common inherited ataxia worldwide [98]. PolyQ diseases are age-related, 
progressive disorders that typically first manifest in midlife, leading to death 15-30 years 
later [99]. A common neuropathological hallmark in SCA3 is the accumulation of 
ubiquitin-positive nuclear inclusions in neurons [100]. It has been reported that patients 
with SCA3 have been shown to present parkinsonian symptoms [101]. Recent studies 
have shown that ataxin-3 interacts with Parkin [102] and mutations in ATXN3 can 
deubiquitinate parkin directly and reduce the extent of parkin ubiquitination in cells 
[102]. The poly (Q) expansion mutant form of ataxin-3 promotes parkin degradation by 
autophagy. Ataxin-3 has not been directly linked to PD however its interaction with 




been linked to parkinsonian phenotypes. Thus, a deeper understanding of Ataxin-3 





Misfolding, aggregation, and aberrant accumulation of proteins are hallmarks of many 
neurodegenerative diseases including PD. Chaperones and cochaperones help guide and 
execute protein folding as well as shuttling proteins that are destined for degradation 
[103]. The Bcl-2 associated athanogene 5 (BAG5) is a co-chaperone known to act in both 
cell survival and cell death pathways. Bag5 has been shown to interact with HSP70 
molecular chaperone as well as Parkin [104], and this interaction with Parkin hinders its 
function in mitophagy resulting in cell death [105]. It has been shown that BAG5 delays 
parkin recruitment to mitochondria following mitochondrial depolarization, therefore 
impairing mitophagy and enhancing cell death [105]. The mechanism by which BAG5 
impedes Parkin recruitment to mitochondria is not clear however and is in direct 
contradiction to Bag2 which enhances Parkin’s recruitment to mitochondria [104]. It has 
been reported that physiological stress increases BAG5 expression [106] however 
conflicting evidence has shown that BAG5 can either play a neuroprotective role as well 
as a neurotoxic role.  
BAG5 has been demonstrated to directly interact with PINK1, and regulated 
PINK1 degradation via the UPS, and in addition protected mitochondria against MPP+ 
[107]. These findings suggested that BAG5 played an important role in stabilizing PINK1 
by decreasing the ubiquitination of PINK1. Upregulation of BAG5 has also been shown 




induced with MPP+ an apoptosis inducer [108]. Lastly, BAG5 has also been shown to 
interact with DJ-1 and reduces the level of DJ-1 dimers in the mitochondria, which 
suggests that BAG5 inhibits mitochondrial translocation of DJ-1 [109]. The role BAG5 
plays in neurodegeneration is yet to be revealed due to conflicting evidence of its role 








2.0. Specific aims 
The primary objective of this research is to achieve a deeper understanding of pathways 
that contribute to neuronal cell death in PD, examine the relationship between PD-related 
proteins, and discover the involvement of miRNAs in PD.  
Specific aims include: 
1.  Evaluate and verify specific protein targets of miRNA candidates involved in PD. 
2. Investigate what role miR-335-5p and miR-3613-3p play in the regulation of key 
PD related proteins. 
3. Examine whether elevated levels of miRs in PD patients play a neuroprotective or 
neurotoxic role in neurons. 
4. Investigate the regulation of ATG5, ATXN3, and BAG5 by miR-335-5p and 







2.1. Materials and Methods 
Buffers 
 
Universal buffers and their composition used in various protocols are listed below. 
Specific buffers are described together with the specific protocols. 
 
Lysis buffers 
The recipes for the lysis buffers used during this dissertation are given here.  
Following is the list of protein localization and lysis buffer used:  
Protein Localization   Buffer recommended 
Whole cell    NP-40 or RIPA 
Cytoplasmic (soluble)   Tris-HCl 
Cytoplasmic (cytoskeletal   Tris-Triton 
Bound) 
Membrane bound   NP-40 or RIPA 
Nuclear    RIPA 
Mitochondria    RIPA 
Please consult separate protocols for sub-cellular fractionation. 
 
Nonidet-P40 (NP40) buffer 
150mM NaCl, 1% NP-40, 50mM Tris at pH8.0, and 2mM EDTA 
 
Radio Immuno Precipitation Assay buffer (RIPA) 
150mM NaCl, 1% NP-40, 50mM Tris at pH 8.0, 0.5% Sodium deoxycholate, and 0.1% 
Sodium  
Dodecyl sulfate (SDS). 
 
Tris-HCl buffer 






100mM NaCl, 1% Triton X-100, 10mM Tris at pH 7.4, 0.5% Sodium deoxycholate, 0.1% 
SDS,  
10% Glycerol, 10mM EDTA, and 10mM EGTA. 
 
Western Blot analysis buffers  
The recipes for buffers used for western blot analysis including buffers required for 
pouring  
Polyacrylamide gels are listed below. 
 
Table 1.1. SDS Polyacrylamide gel recipe  
   
Component Stacking gel 
Resolving 
gels       
  4% 8% 12% 15% 20% 
Deionized water (DIW) 6.15ml 4.73ml 3.4ml 2.4ml 730ul 
30% Acrylamide 1.25ml 2.67ml 4ml 5ml 6.67ml 
1.5M Tris Buffer pH 8.8  -  2.5ml 2.5ml 2.5ml 2.5ml 
0.5M Tris Buffer pH 6.8 2.5ml  -    -  -  - 
10% SDS 100ul 100ul 100ul 100ul 100ul 
10% APS  50ul 50ul 50ul 50ul 50ul 
TEMED 10ul 5ul 5ul 5ul 5ul 
                   
30% Acrylamide solution is 29.2% acrylamide and 0.8% N’,N’-bis-methylene-
acrylamide. 
 
Tris Buffer (1.5M at pH 8.8, 0.5M at pH 6.8) 
Tris base 54.46g and 18.15g was dissolved in DIW; pH was adjusted with 6N HCl to 8.8 
and 6.8  





Running buffer (10X) and Transfer buffer (10X) 
Stock solutions (10X) for running and transfer buffers were prepared with 3.84M Glycine 
and  
0.5M tris base. For running buffer 2% SDS was added. 
 
Tris Buffer Saline (TBS) (10X) 
TBS stock solution (10X) was prepared by dissolving 160.1g NaCl and 48.45g tris-HCl; 
pH was  
adjusted to 7.6 with HCl to make a 2L stock solution. 
 





E.coli DH5; (FS/endA1 hsdR17(rkSmk+), supE44, thi1, recA1, gyrA(Nalr),  
gyrA96(Nalr), 
relA1, Δ(lacZYA=argF) U169, deoR (Φ80dlac Δ(lacZ) M15)) was used For propagation 
and  







pJET 1.2/blunt (Appendix. A) (Thermo Fischer Scientific) was used for routine 
subcloning and  
DNA manipulations.  
pcDNA3 (Appendix A-) (Thermo Fischer Scientific) was used for heterologous protein  
expression and stable cell line generation in mammalian cells. 
 
Growth media and growth conditions  
Bacteria were grown using Lysogeny broth (LB-1% Tryptone, 0.5% Yeast extract, and 
1%  
NaCl) in liquid cultures or LB-agar (1.5% agar added to LB) as colonies. Super optimal 
broth  
With catabolite repression (SOC – 2% Tryptone, 0.5% Yeast extract, 0.02% KCl, 0.25% 
MgSO4  
and 0.06% NaCl, and 036% Glucose; pH 7.0) was used during transformation for 
recovery of transformants. Liquid cultures for DH5 were grown in a shaking incubator 
at 250rpm at 37C. Colonies were grown on LB-agar plates incubated overnight (O/N) in 
an incubator at 37C. Colonies were picked using sterile pipette tips and added to culture 
tubes for growing liquid cultures with antibiotic selection. 
Antibiotic Selection 
Antibiotic selection was carried out to select colonies ad grow cultures of positive clones. 
Antibiotics were added to medium prior to use (LB) or before pouring plates (LB-agar). 
Ampicillin (100g/ml) was used as selection marker for pJET 1.2/blunt, pcDNA3 







Primers used for various cloning experiments as well as semi-quantitative PCR and qRT-
PCR experiments are listed below (Table). Restriction endonuclease cutting sites are 
underlined and in italics, and mutations are in bold/codon is underlined, if applicable. 
Table 1.2. List of Primers 
No. Name of Primer (RE site/Tag) Sequence with RE site & Tag 
      
1)  pcDNA3 forward (100bp MCS) CGCAAATGGGCGGTAGGCGTGTACG 
2) pcDNA3 reverse (MCS100bp) TGGCACCTTCCAGGGTCAAGGAAGG 
3) pJET1.2 forward (_MCS) CGACTCACTATAGGGAGAGCGGC 
4) pJET1.2 reverse (MCS_) AAGAACATCGATTTTCCATGGCAG 
5) scaRNA17 forward AGAGGCTTGGGCCGCCGAGC 
6) RNA U6 forward CGCTTCGGCAGCACATATAC 
7) cel-miR-39-3p forward ATTCACCGGGTGTAAATCAGC 
8) hsa-miR-335-5p forward ATTCAAGAGCAATAACGAAAAATGT 
9) hsa-miR-3613-3p forward ATACAAAAAAAAAAGCCCAACC 
10) hsa-miR-6865-3p forward ATACACCCTCTTTCCCTACC 
11) hsa-miR-4797-5p forward ATGACAGAGTGCCACTTACTG 
12) hsa-miR-455-3p forward ATGCAGTCCATGGGCATATAC 
13) hsa-miR-3910-1 forward ATTGCTGTCAGTTTTTCTGTTGC  
14) hsa-miR-16-2-3p forward ATCCAATATTACTGTGCTGC  






Polymerase Chain Reaction (PCR)  
PCR was performed to amplify genes of interest from cDNA, and to screen for colonies 
of positive transformants by colony PCR.  
PCR to amplify genes for subsequent cloning: 
Phusion DNA polymerase (Thermo Fischer Scientific) was used to amplify genes or 
gene products due to its high-fidelity and to get accurate, blunt ended PCR products 
which were first used for cloning into the shuttle vector pJET 1.2 vector. 
PCR reactions were setup as follows: 
Component 1x reaction (μl) 
    
5x Phusion HF buffer 4 
10mM dNTPs 0.2 
Phusion DNA Polymerase 0.2 
Forward primer 1 
Reverse Primer 1 
Vector  1 
DIW 12 
Reactions were setup with the following program: 
Step Temp. (ºC) Time 
1 98 1min. 
2 98 30sec. 
3 49 30sec. 
4 72 
30sec/kb of PCR 
product 
5 
Goto step 2, 
30x  
6 72 7min 





PCR to screen for bacterial colonies 
Taq PCR Master mix kit (Qiagen, Inc.) was used to perform colony PCR for screening 
positive transformants. Colonies were grown on LB-agar were picked using sterile pipette 
tips and added to culture tubes with LB media and appropriate antibiotic selection. 
Cultures were grown O/N at 37C in an incubator at 250rpm. 1l of liquid culture was 
used as template in each PCR. Specific primer pairs (Table) were used to either confirm 
the presence and/or orientation of gene product. The reactions were setup as follows: 
Component 1x reaction (μl) 
PCR Master Mix (2X) 10 
Forward Primer 1 
Reverse Primer 1 
Cultures/colony 1 
DIW 7 
Reactions were setup with the following program: 
Step Temp. (ºC) Time 
1 95 2min. 
2 94 1min. 
3 58 1min. 
4 72 1min. 
5 
Goto step 2, 
34x  
6 72 5min. 






Nucleic acid isolations 
All DNA isolations were performed using commercial kits following manufacturer’s 
protocol. GeneJET plasmid miniprep kit (Thermo Fischer Scientific) was used for small 
scale routine isolation of plasmid DNA. QIAquick PCR purification kit (Qiagen) was 
used to clean up the PCR product to remove components of the PCR mix to obtain 
purified DNA product for further experiments. GeneJET Gel Extraction kit (Thermo 
Fischer Scientific) was used to clean up the PCR product to remove primer dimers, and 
other non-specific DNA bands. 
Nucleic acid measurement 
Nucleic acid in the form of plasmid DNA, genomic DNA, and cDNA were always, at 
various stages, ran on agarose gels or NanoDrop 2000 Fluorospectrometer (Thermo 
Fischer Scientific) for quality control (QC) purpose.  
Nucleic acid manipulation 
pJET cloning 
All genes were first cloned by blunt end cloning into the pJET 1.2 vector using the 
CloneJET PCR cloning kit (Thermo Fischer Scientific) according to the manufacturer’s 
protocol. Ligated products were transformed into E. coli DH5- cells and colonies were 
grown under ampicillin selection, and screened for positive transformants using 





Restriction endonuclease digestions 




 Water (Nuclease free) 3 
10X FastDigest buffer 1 
DNA 5 
Enzyme 1 0.5 
Enzyme 2 0.5 




pJET 1.2 BgIII (2 sites) 
    
pcDNA3 
RE flanking the 
gene 







Ligation (Thermo Fischer Scientific) reactions were setup as follows: 
Component (μl) 
Digested insert 8 
Digested Vector (10-
50ng) 0.5 
T4 DNA ligase 0.5 
10X T4 DNA ligase buffer 1 
Nuclease free water 0 
Total 10 
Ligation mix was incubated at RT for 20-30mins. Ligation mix was used for 
transformations. 
Bacterial Transformations 
DH5- cells were thawed on ice and typically 5l of the ligation reaction was added to 
the cells. The transformation mix was incubated on ice for 30min. At the end of the 
incubation, cells were subjected to heat shock at 42C for 45sec. Immediately followed 
by incubation on ice for 2-3min. 900l SOC or LB media was then added to the cells and 
the cells were incubated at 37C for 1hr with shaking. Cells were plated onto appropriate 
LB-agar plates (antibiotic selection). The LB-agar plates were incubated at 37C for at 





Characterization of bacterial transformants 
Bacterial transformants were generally analyzed by two methods mentioned below. 
Positively transformed colonies were verified by DNA sequencing at the Yale DNA 
analysis facility, CT. The sequencing data was analyzed using BLAST by NCBI. 
Colony PCR for colony screening 
1l of O/N liquid bacterial culture were used for PCR reactions and the remaining was 
used for subsequent DNA isolation. PCR reactions were setup using the Taq PCR Master 
Mix Kit (Qiagen) and the primer pairs either flanking the MCS in vector, Flanking the 
gene of interest or one internal primer along with vector specific primer. Samples were 
run on a 1% agarose gel and colonies that gave the correct sized DNA fragment was used 
for further analysis.  
Agarose gel electrophoresis 
PCR products or restriction digests were analyzed on 1% agarose gel electrophoresis. The 
products were mixed with loading buffer (6X Loading buffer. 30% glycerol, 0.25% 
bromophenol blue) and ethidium bromide in order to visualize the separated DNA 
fragments on a UV transluminator. Tris-acetate-EDTA buffer was used to make the gels 
and also running buffer. The gels were prepared by adding the appropriate amount of 
agarose to 1X TAE buffer (40mM Tris base, 20mM Glacial acetic acid, and 1mM EDTA 
at pH 8.0) followed by melting the agarose by heating in a microwave oven, adding 
ethidum bromide, pouring into a gel cassette and allowing agarose gel to solidify. HiLo 





RNA processing and analysis 
RNA isolation 
Total RNA was extracted using specialized kits following the manufacturer’s protocol. 
All the RNA samples were quantified and quality controlled on a Nanodrop 2000 
(Thermo Scientific, MA). 
RNA isolation (mRNA from mammalian cells) 
All RNA isolations were performed 24hrs post-transfection or from stable cells in 
triplicate. Total RNA was extracted from mammalian cells by using the RNeasy Mini kit 
(Qiagen) and GeneJET RNA purification kit following manufacturer’s protocol. Total 
RNA (enriched small RNA) was isolated using the miRCURY RNA isolation kit- cell 
and plant (Exiqon). 
RNA isolation (Small RNA from mammalian cells) 
All RNA isolations were performed 24hrs post-transfection in triplicate. Total RNA was 
extracted from mammalian cells using the miRCURY RNA isolation kit – cell and plant 






All RNA samples were treated with 1 unit/g of RNA of DNase-1 (Thermo Scientific) 
for 30min at 37C followed by 10min at 65C with 50mM EDTA. The DNase 1-treated 
RNA was used to synthesize first strand cDNA using a variety of commercial kits. 
cDNA synthesis (from mRNAs) 
The DNase 1-treated RNA was used to synthesize first-strand cDNA, by using the 
RevertAid First Strand cDNA Synthesis kit and an oligo dT primer (Thermo Fischer 
Scientific) following the manufacturer’s instructions. The cDNA samples were used for 
PCR amplifications of genes of interest for cloning, semi-qualitative PCR, and qRT-PCR. 
cDNA synthesis (From small RNAs) 
For small RNAs, cDNA was synthesized using DNase 1-treated RNA and the qScript 
miRNA cDNA synthesis kit (Quanta Biosciences) following manufacturer’s protocol. 





Reactions were setup as follows in two steps: 
Poly(A) Tailing reaction 
Component Per reaction (uL) 
Poly(A) Tailing Buffer 
(5X) 
2 
RNA (up to 1ug total) up to 7uL 
Nuclease free water Variable 
Poly(A) Polymerase 1 
Mix components from above and incubate at 37C for 60mins followed by 5mins at 
70C. Centrifuge and keep on ice for cDNA synthesis. 
First strand cDNA synthesis reaction 
Component Per reaction (uL) 
Poly(A) tailing reaction 








Incubate reaction mix for 20mins at 42C followed by 5mins at 85C, and allow to 





Semi-quantitative RT-PCR (mRNA and small RNAs) 
cDNA was used for semi-quantitative RT-PCR using appropriate primer pairs (Table) 
and PCR protocol for 25 cycles. The samples at the end of the reactions were run on 1% 
agarose (for mRNAs). The gel images were analyzed at the end, to semi-quantitatavely 
measure gene expression. GAPDH (mRNAs) and U6 (small RNAs) were used as controls 
in all the semi-quantitative RT-PCR experiments. 
Real-time qPCR 
Equal amount of cDNA in each sample was used to perform qRT-PCR. All qRT-PCR 
were performed using PerfeCTa SYBR GREEN SuperMix for IQ containing 
AccuStart Taq DNA polymerase (Quanta Biosciences) for 45 cycles followed by 
dissociation steps with a MyiQ single color Real-time PCR detection system (Bio-Rad, 
CA). No template control (NTC) was employed.  
Reaction was setup as follows: 
Component Per reaction (uL) 




Assay Primer (10uM) 
1 
PerfeCTa Universal PCR 
Primer (10uM) 
1 






Real-time qPCR (mRNA) 
For mRNA qRT-PCR, gene specific primers, at a concentration of 1uM were used. The 
qRT-PCR protocol was as follows: Intial denaturation at 95C for 2mins followed by 35 
cycles of denaturation at 95C for 15s, annealing at 60C for 45s and extension at 72C 
for 40s. GAPDH or Actin was used as reference RNAs for normalizing Cq values to 
calculate relative expression. 
Real-time PCR (Small RNA) 
qRT-PCR for small RNA quantification were performed with reaction volume of 20l 
with small RNA-specific forward primers and a PerfeCTa Universal PCR primer at a 
final concentration of 0.2uM. The qRT-PCR protocol involved initial denaturation at 
95C for 2min followed by 45 cycles of denaturation at 95C for 15s, annealing at 60C 
for 30s and extension at 72C for 15s, which was followed by dissociation steps of 0.5C 
increments. scaRNA and U6 were used as reference small RNAs for normalizing Cq 
values whereas cel-miR-39-3p was used as spike-in control. The standard curve for cel-





Tissue culture and processing 
Tissue culture guidelines: 
Table 1.3 Tissue Culture Guidelines 
 
Conversion chart used for tissue culture experiments. Invitrogen.  
Cell culture and stock information 
Sh-SY5Y cells were cultured in a base medium (1:1 mixture of DMEM/Ham’s-F12) 
(Invitrogen) supplemented with fetal bovine serum (FBS) (Atlanta biologics) at a final 
concentration of 10% and 2mM GlutaMax (Invitrogen) in a 5% CO2 atmosphere at 37C. 




to maintain confluency. Full medium supplemented with 5% DMSO was used as freezing 
medium to cryopreserve cells. 
Transfections 
The transfection experiments were performed the day after seeding, for each plasmid 
transfection, 0.5g plasmid DNA was diluted with 50l Opti-MEM (Life technologies, 
Grand Island, NY) and 1.25l Lipofectamine 2000 (Invitrogen) was diluted with 50l of 
Opti-MEM and incubated for 5min at RT. After incubation both solutions were mixed 
and incubated for 15mins at RT. This transfection mix was diluted to 2ml with Opti-
MEM and added to cells for transfection. Cells were incubated at 37C in 5% CO2 
atmosphere for 4-6hrs. before replacing with full media. Appropriate empty vector 
controls were used with each transfection experiment. The cells were used 24hr (RNA) 
and 48hr (Protein) after transfection  and incubation for downstream processing. 
Transfection (miRs) 
The day after seeding cells were transfected using scrambled control mimic/inhibitor and 
mimic/inhibitor of miR-335-5p, miR-3613-3p, and miR6865-5p obtained from 
mirVana (Life Technologies), at a final concentration of 20nM. 2l of each RNA 
(20M stock), was diluted with 100l of Opti-MEM and 7l of Lipofectamine RNAiMax 
(Invitrogen) was diluted with 100l of Opti-MEM and incubated for 5min at RT. The two 
solutions were then mixed together and incubated for 15min at RT. The transfection mix 
was diluted to 2ml with Opti-MEM, added to the cells and incubated at 37C in 5% CO2 




for transcript analysis by qRT-PCR and after 48hr for protein analysis by Western 
Blotting. 
Cell Treatments 
All treatments were performed in serum-free complete media at 37C for 6hr, unless 
indicated otherwise. Untreated cells were maintained in serum-free complete media at 
37C for 6hr as well. Various reagents used for treatments are given in the table below. 
Table 1.4. Cellular Treatments 
Reagent Concentrations used  Supplier 




100μM Acros, Pittsburgh, PA 
Rotenone 1μM, 10μM, 50μM Sigma Aldrich 
6 hydroxydopamine (6-
OHDA) 
1μM, 10μM, 100μM Sigma Aldrich 
Cell Harvesting 
Cells growing at 85-90% confluency were trypsinized and removed from the plate. Cell 
suspension was spun down by centrifugation at 500xg at 4C for 5min, supernatant was 
discarded and cells were washed with 1ml ice cold PBS and spun down again. 
Supernatant was discarded and lysis buffer (RIPA) was added to cell pellet, pipetting up 




a spin at max speed (25,000xg) for 10min. Supernatant was collected and placed in 
another labeled centrifuge tube and kept at    -20C for future processes. 
Protein analysis 
Western blot analysis 
Western blot analysis was performed using the following protocol: 
Sample preparation: Protein lysates were always thawed on ice and 5x reducing dye was 
added to samples followed by boiling at 95C for 5min. Samples were than cooled on ice 
for 1min, and subjected to quick centrifugation to collect condensate.  
SDS-PAGE and Blotting: Whole cell lysates were generally prepared using RIPA buffer. 
Protein estimation was performed using the DC Protein assay kit (Bio-Rad, Hercules CA) 
showing <10% variation in protein concentrations among the same fractions. 4l of 5x 
Laemmli sample buffer (50mM Tris pH 6.8, 0.1% SDS, 20% glycerol, 0.2% 
bromophenol blue) with BME was added to 16l of whole-cell lysates. Samples (20l) 
were subjected to SDS-PAGE by using the mini-Protein Tetra system (Bio-Rad) with 
12% polyacrylamide slab gels at 100V for 90min in running buffer (192mM glycine, 
25mM Tris Base, 0.2% SDS). The separated proteins were transferred to PVDF 
membranes (Pall Life Sciences, Ann Arbor, MI) in transfer buffer (192mM glycine, 
25mM Tris Base, 20% methanol, and 0.005% SDS) at 200mA for 45min, followed by 
blocking in 5% nonfat dry milk/TBS-T (137mM NaCl, 15.4 mM Trizma HCl, 0.1% 
Tween 20, pH 7.6) for 1 hour at RT. After blocking the membrane was incubated with 




nonft dry milk overnight at 4C and washed with TBS-T three times for 10min. After 
wash appropriate secondary antibody (Jackson Immunoresearch, West Grove, PA) at 
1:10,000 dilution for 1hr at RT. The membrane was washed with TBS-T three times for 
10min each. The membrane was developed using the Pierce ECL Western blot substrate 
(Therno Fischer Scientific) and signal detection was recorded with the molecular imager 
Chemi Doc XRS1 imaging system (Bio-Rad). PageRuler Unstained Broad Range 
Protein Ladder, which has each protein containing an integral Strep-tag II Sequence, was 
used as a marker for all the gels and blots. 
Table 1.5. List of Primary and Secondary antibodies 
  
Antibody (Dilution used 1:1000 for 
primary and 1:10000 used for 
secondary 
Vendor 
  Primary Antibodies   
1) Rabbit polyclonal anti-GAPDH Santa Cruz Biotechnology 
2) Mouse monoclonal anti-PARKIN Santa Cruz Biotechnology 
3) Rabbit polyclonal anti-ATXN3 Abcam 
4) Mouse polyclonal anti-BAG5 Santa Cruz Biotechnology 
5) Rabbit polyclonal anti-ATG5 Santa Cruz Biotechnology 
6) Rabbit polyclonal anti-SOD1 Santa Cruz Biotechnology 
7) Rabbit polyclonal anti-GBA Santa Cruz Biotechnology 
8) Goat polyclonal anti-Park13 Santa Cruz Biotechnology 
9) Rabbit polyclonal anti-SNCA Abcam 
10) Rabbit polyclonal anti-LRRK2 Abcam 
11) Rabbit polyclonal anti-PINK1 Novus Biologicals 
12) Mouse monoclonal anti-DJ-1 Enzo Life Sciences 
13) Mouse monoclonal anti-Actin Santa Cruz Biotechnology 
  Secondary Antibodies   
1) Goat anti-Rabbit IgG (H+L)-HRP Jackson Immunoresearch 
2) Donkey anti-Goat IgG (H+L)-HRP Jackson Immunoresearch 
3) Goat anti-Mouse IgG (H+L)-HRP Jackson Immunoresearch 





Cell Viability assay 
Cell viability was measured using the neutral red uptake assay 48hr post transfection. 
Cells were washed with PBS, 100l of neutral red working solution (40g/ml) added to 
each well and plates were incubated for 2hr. Cells were then washed with PBS, neutral 
red extracted using 150l of destain solution (50% ethanol, 1% glacial acetic acid, 49% 
deionized water) per well and the plates were subjected to shaking for 10min. 
Absorbance was measured at 540nm using an Epoch microplate spectrophotometer 
(Bioteck)  
Breadford assay for protein estimation 
Protein concentrations were measured using protein assay kit II and DC protein assay kit 
(Bio-Rad, Hercules, CA) Bovine serum albumin was used to prepare incremental 
standard solutions from 0.05-1.0mg/ml. Assays were performed in 96-well micro-plates 
and the colormetric reading were recorded using Epoch microplate spectrophotometer 
(Bioteck). Protein samples were diluted from 1:10 to 1:100 for the assay. Samples for 
loading were prepared based on the concentrations obtained by the assay. 
Image analysis and statistical analysis 
ImageJ software (NIH, Bethesda, MA) and IQTL software (GE healthcare) was used to 
analyze  





unless indicated. Statistical analyses were performed using Microsoft excel unless 
otherwise  
















Main Project: microRNA regulation of key PD proteins 
Introduction 
PD is the most common, progressive neurodegenerative movement disorder 
characterized by the loss of dopaminergic (DA) neurons in the substantia nigra pars 
compacta (SNpc) [110]. The etiology of PD has been linked to age, environmental 
factors, and mutations in several genes including SNCA, Parkin, and PINK1 [111]. 
Aggregation of misfolded proteins causing inclusion bodies is a hallmark of PD [112]. 
The presence of LBs enriched in the protein a-syn plays a major role in neuronal cell 
death enhancing the progression of Parkinson’s like neurodegeneration [113, 114]. The 
E3 ubiquitin ligase Parkin plays a prominent role in both familial and sporadic PD, 
although Parkin is neuroprotective and promotes neuronal cell survival its loss of 
function causes mitochondrial dysfunction[115, 116]. Parkin, along with its associated 
molecular chaperone HSP70, are found in LBs in sporadic PD [117]. BAG5 (bcl-2-
associated athanogene 5) is a member of the BAG family and has been shown to form a 
complex with HSP70 [118], and interact with Parkin. This interaction has deleterious 
functional consequences by inhibiting HSP70 chaperone activity and Parkin E-3 Ligase 
activity causing an influx of protein aggregation [119].  
Non-coding RNAs are involved in many regulatory cellular processes and make 
up a significant portion of our genome. miRNAs are small non-coding RNAs which are 
20-22 nucleotides in length and function in gene regulation and silencing [120]. miRNAs 
have also been extensively studied as potential biomarkers due to their extracellular 
stability and altered disease state expression [121] A recent study highlighted the 




differentially expressed in patients with PD allowing for classification of PD within a 5% 
error [122]. While this is taking a potential diagnostic approach there have been studies 
which show regulatory effects of miRNAs in PD. One specific study showed the 
regulatory effects of miR-34b/c on the key Parkinson’s proteins Parkin and DJ-1 causing 
loss in cell viability [123]. A considerable number of miRNAs have been reported for 
their regulatory roles in PD [124]. We investigated miR-335-5p and miR-3613-3p which 
have been associated with an array of diseases from cancer to gestational diabetes, 
however there are no studies to date that show the relationship between miR-335-5p and 
miR-3613-3p and PD.  
In this study we show that miR-335-5p and miR-3613-3p levels are significantly 
elevated in PD patients as compared to healthy individuals which further corroborated 
our previous findings [125]. This increase in miRNA expression was also prevalent in 
post-mortem frontal cortext samples for both PD and age-matched controls. We further 
report that miR-335-5p and miR-3613-3p overexpression may have a neuroprotective 
function as it increases cell viability in SH-SY5Y cells induced with oxidative stress. We 
also show that oxidative stress causes miR-335-5p and miR-3613-3p overexpression not 
seen under normal, non-stressed conditions. This increase leads to increased levels of 











In our previously reported longitudinal study we identified, verified and validated miR-
335-5p, miR-3613-3p, miR-6865-3p as differentially expressed in 370 PD (drug-naïve) 
and control serum samples from the Norwegian ParkWest study and in 64 PD (drug-
naïve) and control serum samples from NY Parkinsonism in UMeå (NYPUM) study 
[125]. We further showed that that miR-335-5p, miR-3613-3p, miR-6865-3p 
(PARKmiRs), and any two combinations of the PARKmiRs, were robust classifiers of 
PD at baseline diagnosis [125].To expand on these findings and to gain insight into 
whether the increased miRNA levels in serum may reflect changes in brain miR profiles 
we isolated small RNAs from post-mortem frontal cortex brain samples of PD patients 
and age matched healthy control individuals. RNA isolation was performed on 9 PD 
brains and 6 age matched control brain samples, and expression levels were measured 
using a SYBR Green-based quantitative reverse-transcriptase polymerase chain reaction 
(qRT-PCR) assay. scaRNA17 was used as a small RNA reference for normalizing the 
qRT-PCR Cq values and cel-miR-39-3p was used as a spike-in control. The spike in 
control was included to ensure that recovery of small RNA was consistent across the 
samples. The results from the qRT-PCR assay revealed that both miR-335-5p and hsa-
miR-3613-3p levels were significantly upregulated in PD brains (Fig.1) compared to 
healthy age matched controls. We also tested six other PARKmiRs discovered in our 
previous study [121] revealing that hsa-miR-6865-3p was also significantly upregulated 




3613-3p. The finding that miR-335-5p and miR-3613-3p levels are elevated in frontal 
cortex brain samples of PD patients, complements our previous data showing elevated 
PARKmiRs levels in PD serum, possibly suggesting a mode of miR release into serum 
from the brain.  
 
Figure 1.1 Upregulation of PARKmiRs in brain samples. qRT-PCR comparison of 
post-mortem frontal cortext brain samples of Parkinson’s patients and healthy age-
matched controls showing significant upregulation of PARKmiRs hsa-miR-335-5p, hsa-
miR-3613-3p, and hsa-miR-6865-3p in PD brain samples compared to control. All above 







Overexpression of miR-335-5p and miR-3613-3p increase cell viability in response 
to oxidative stress 
 
To investigate whether overexpression of miR-335-5p and miR-3613-3p has any 
significant effect on cell viability we performed a neutral red assay on SH-SY5Y cells 
overexpressing the two PARKmiRs, independently. To impose stress on the SH-SY5Y 
cells we also treated cells with 100µM H2O2 and 100µM L-Dopa for six hours followed 
by the neutral red assay. We observed no change in cell viability in SH-SY5Y cells 
overexpressing a control mimic or the miR-335-5p and miR-3613-3p mimics (miR-335M 
and miR3613M) in untreated cells as expected (Figure 2A). However, after six hours of 
treatment with 100µM H2O2 we observed a significant loss in viability in cells expressing 
the control mimic (Figure 2A). Interestingly, cells overexpressing miR-335-5p and miR-
3613-3p showed a significant rescue in cell viability as compared to the control mimic 
expressing cells suggesting that both PARKmiRs may have a possible protective role 
(Figure 2A). A similar result was also observed in response to 100µM L-Dopa treatment 
(Figure 2A) suggesting that both PARKmiRs have a protective effect in response to 
oxidative stress, either directly by H2O2 treatment or indirectly in response to L-Dopa 
exposure.  
This observed protective effects of both miR-335-5p and miR-3613-3p on SH-
SY5Y cells, in response to oxidative stress, may explain the elevated levels of both 
PARKmiRs in PD serum [121] and PD brain samples (Figure 1). These elevated levels of 
both PARKmiRs may indeed contribute to mitigating neurodegeneration in PD. To 




Dopa in a dose dependent manner for six hours followed by cell viability analysis. We 
observed, as expected, a progressive loss in cell viability with increasing concentration of 
both H2O2 and L-Dopa (Figure 2B). We then performed qRT-PCR on the wild-type SH-
SY5Y cells exposed to 100µM H2O2 and 100µM L-Dopa for six hours, which showed 
that both endogenous PARKmiRs are significantly upregulated in response to oxidative 
stress as compared to untreated cells (Figure 2C). Combined these results suggest that the 
elevated levels of miR-335-5p and miR-3613-3p in PD brains and PD serum may 











Neutral red assay and fluorescence image analysis showing significant increase in cell 
viability in response to H2O2 and L-Dopa treatments in cells overexpressed with miRs. 
(A) miR-335-5p and miR-3613-3p mimic overexpression shows significant rescue in cell 
viability for SH-SY5Y cells treated with 100M H2O2 or 100M L-Dopa. (B) Dose-
dependent curve of control SH-SY5Y cells treated with H2O2 and L-Dopa showing 
increased loss in cell viability with increasing concentrations of treatments. (C) qRT-PCR 
expression of miR-335-5p and miR-3613-3p respectively showing significant increase in 
expression in response to H2O2 and L-Dopa treatments. All above (n=4), * p < 0.05; ** p 
< 0.01; *** p < 0.001. 
 
Increased expression of miR-335-5p and miR-3613-3p has neuroprotective effects 
 
As a hallmark of PD onset is the aggregation of a-syn and progression is directly 
associated with missense mutations, duplication and triplication events in the a-syn 
encoding gene SNCA  [26] we wanted to more fully understand how miR-335-5p and 
miR-3613-3p function in a neurotoxic environment similar to that observed in PD. To 
this end we created SH-SY5Y cell lines that overexpressed wild-type a-syn triplication 
mutation and the two clinical a-syn variants a-syn-A53T and a-syn-E46K point mutations 
[76, 77]. To confirm overexpression of wild-type a-syn, a-syn-A53T and a-syn-E46K in 
our stable SH-SY5Y cell models we performed western blot analysis using a monoclonal 
anti-a-syn antibody. The western blot analysis showed that all three cell lines 
overexpressed a-syn, a-syn-A53T and a-syn-E46K to a similar level showing significant 
overexpression of the 14kDa a-syn monomer as compared to cells expressing the pcDNA 




335-5p and miR-3613-3p in the three a-syn cell models we performed miR extraction 
from the cells followed by qRT-PCR analysis. Interestingly, we found that both miR-335-
5p and miR-3613-3p were significantly elevated in cells overexpressing wild-type a-syn 
and in cells overexpressing the two clinical variants a-syn-A53T and a-syn-E46K as 
compared to cells expressing pcDNA3 alone (Figure 3B).  
Closer analysis of the data also revealed that the expression profiles of miR-335-
5p and miR-3613-3p differed between the different cell lines except for a-syn-A53T 
where the expression of both PARKmiRs was similar (Figure 3B). It is unclear why the 
expression profiles of miR-335-5p and miR-3613-3p differ between the different a-syn 
mutant cell lines but it may be due to differences in severity of cellular toxicity caused by 
the mutations. To further investigate whether overexpression of wild-type or mutated a-
syn has an effect on cell viability we performed neutral red assays on the three cell lines 
and showed that overexpression of wild-type a-syn, a-syn-A53T and a-syn-E46K had no 
significant effect on SH-SY5Y cell viability under normal conditions (Figure 3C).  
As overexpression of wild-type a-syn, a-syn-A53T and a-syn-E46K, coupled with 
exposure to oxidative stress such as H2O2 mimics the neurotoxic environment in PD, we 
wanted to determine whether miR-335-5p and miR-3613-3p can act as neuroprotectors in 
this PD simulated environment.  To accomplish this we transfected miR-335-5p and miR-
3613-3p into SH-SY5Y cell lines overexpressing wild-type a-syn, a-syn-A53T and a-syn-
E46K, respectively. Two days after transfection we treated cells with 100M H2O2 for 
six hours and performed a neutral red assay to quantify cell viability. Our results show 
that miR-335-5p and miR-3613-3p overexpression results in cell viability rescue for all 




viability rescue with only endogenous levels of miR-335-5p and miR-3613-3p implying 
that overexpression of these two PARKmiRs is needed in order to positively effect cell 
viability under neurotoxic stress conditions. These data suggest therefore that miR-335-
5p and miR-3613-3p are acting in a neuroprotective capacity perhaps by regulating genes 
that confer neuroprotection in neurons.  
 




(A) Western blot analysis showing overexpression of monomeric -syn Lane’s 1-4: 
pcDNA3, wt-SNCA (Triplication mutation), E46K, A53T. (B) Overexpression of 
endogenous miR-335-5p and miR-3613-3p in mutant cell lines using qRT-PCR. (C) 
pcDNA3, wt-SNCA, E46K, A53T cells were treated with neutral red and cell viability 
was assayed (n=3, ns- no significance). (D) Indicated cells were treated with 100uM 
H2O2 for 6 hours followed by neutral red assay for cell viability Lane 1-4, Untreated, 
Treated, miR-335-5p treated, miR-3613-3p treated ( n=3, *p< 0.05, **p<0.01, t test). 
 
ATG5, Ataxin-3, and BAG5 are all regaulated by miR-335-5p and miR-3613-3p 
 
To identify potential targets of miR-335-5p and miR-3613-3p we used both in silico 
prediction analysis (miRTarBase, Partek Genomics Suite) and our previously reported 
LC-MS data [121]. From this analysis we identified 1,516 putative protein targets with 
high enrichment scores for miR-335-5p and miR-3613-3p. This putative protein target list 
was then further analyzed for proteins with known associations to neurodegenerative 
pathways, PD, and other fundamental neuronal processes. We found that ATG5, Ataxin-
3, and BAG5 were all predicted targets of miR-3613-3p, however miR-335-5p did not 
target any of these. These targets were of interest because of their direct correlation with 
PD as well as other neurological diseases. We continued to investigate the regulation of 
ATG5, Ataxin-3 (ATXN3), and BAG5 with respect to miR-335-5p because of its 
previously recorded regulatory effects on Leucine Rich Repeat Kinase 2 (LRRK2) which 
BAG5 has been shown to directly interact with [126]. Recently, ATG5 has been shown to 
contribute to the protection of dopaminergic neurons in a MPTP zebrafish PD model 




influx of aggregated proteins [92]. This was only alleviated when ATG5 was 
overexpressed in cells [111]. ATXN3 has also been shown to be involved in autophagy 
where mutant ATXN3 causes downregulation of BECN1 resulting in decreased 
autophagosome formation [127].  
To further validate our in silico analyses we transfected the miR-335-5p and miR-
3613-3p into SH-SY5Y cells and confirmed overexpression of miRs with qPCR (Figure 
4A), followed by western blot analysis for ATG5, BAG5 and Ataxin-3. We found that 
both miR-335-5p and miR-3613-3p overexpression significantly upregulates the 
expression of Atg5 compared to the control (Figure 4C). Bag5 also showed significant 
upregulation in overexpressed miR-335-5p cells, however we did not observe any 
significant regulation of Bag5 in cells overexpressing miR-3613-3p (Figure 4D-E). 
Interestingly, miR-335-5p had a reverse regulatory effect on Atxn3 by significantly 
downregulating its expression (Figure 4F). We observed a moderate, but significant 
upregulation of Atxn3 in overexpressed miR-3613-3p cells (Fig 4G). It is certainly 
interesting to note that overexpression of miR-335-5p had an effect on all protein targets 
tested suggesting a possible expansive regulatory role miR-335 in these pathways. We 
did not find significant alteration of ATG5, ATXN3, and BAG5 at the mRNA level 
suggesting that a post-transcriptional mechanism was involved in the observed alterations 





Figure 4.1 PARKmiRs 335 and 3613 significantly regulate expression of ATG5, 
BAG5, and ATXN3. 
(A) qRT-PCR analysis showing miR-335-5p and miR-3613-3p in response to mimic 
microRNA transfection. Western blot analysis comparing Control mimic cells (1) with 
miR-335-5p mimic (2) and miR-3613-3p mimic (3). (B, C) Western blot analysis 
showing significant upregulation of ATG5 in both miR-335-5p & miR-3613-3p 
overexpression. (D, E) Western blot analysis showing significant upregulation of BAG5 
in cells overexpressing miR-3613-3p. (F, G) Western blot analysis showing significant 
downregulation of ATXN3 in cells overexpressing miR-335-5p and significant 
upregulation of ATXN3 with cells overexpressing miR-3613-3p. All above (n=4), * p < 







Mutations in ATG5, ATXN3, and BAG5 have been shown to enhance neurodegeneration 
due to misfolded proteins [128], and these mutations have been noted in idiopathic PD 
patients, suggesting that mutations in ATG5, BAG5, and ATXN3 are associated with PD 
[92]. Previous studies have demonstrated that BAG5 functions as a nucleotide exchange 
factor of Hsp70 and also interacts with Parkin to inhibit Parkin E3 ubiquitin ligase 
activity which in turn inhibits Parkin’s ability to ubiquitinate misfolded proteins such as 
alpha synuclein [129]. ATG5 has been shown to play a neuroprotective role in 
dopaminergic neurons by increasing autophagy of misfolded and aggregated proteins. 
This clearance of aggregated proteins mitigated its cytotoxic effects in the neuron [92]. 
ATXN3 repeat expansion mutations have been shown mainly in Spinocerebellar ataxia 
type 3 (SCA3) a neurodegenerative disease in the cerebellum [130]. It has also been 
shown to cause Parkinson’s like phenotypes and previous studies have found that repeat 
expansion mutations occur in early-onset PD [131].  
In our study, we have demonstrated that miR-335-5p and miR-3613-3p are 
unregulated in PD post mortem brain samples corroborating our previous findings [125]. 
In cells over expressing miR-335 and miR-3613 we showed a neuroprotective function 
and a rescue of cell viability when inducing SH-SY5Y cells with hydrogen peroxide 
stress. Interestingly, we also found an increase in endogenous expression of miRs 335 
and 3613 in our mutant cell lines over expressing a-syn variants further corroborating our 
claims that miR expression is increased in neurotoxic conditions. Taking it one step 




peroxide stress we also found an increase in cell viability compared to the control. This 
lead us to believe that miR-335 and miR-3613 are acting in a neuroprotective manner and 
this could be a reason why we see overexpression of both miRs in serum, brain, and 
mutant cell lines.  
In conclusion, we report a novel role for miRs 335 and 3613 as modulators of 
ATG5, ATXN3, and BAG5. We have also shown that overexpression of both miRNAs 
resulted in an increase in cell viability under oxidative stress conditions. The 
understanding of how these miRNAs regulate expression of key targets and the pathways 




Future work would include analyzing the effect mutant versions of Ataxin-3 have on 
Parkin and how it’s down-regulation by miR-335-5p ameliorates the negative effects 

















Neurodegenerative disorders are progressive, debilitating diseases characterized by motor 
and cognitive symptoms caused by neuronal death and dysfunction.  Neurodegenerative 
diseases such as Parkinson’s Disease (PD), Alzheimer’s Disease (AD), Huntington’s 
Disease (HD), Amyotrophic Lateral Sclerosis (ALS) and prion diseases (pD) share 
implicated risk factors such as oxidative stress, aging, environmental factors and protein 
dysfunction [132]. These risk factors, however, manifest distinctly in each disease and 
produce unique pathologies. 
Protein misfolding and aggregation is a common theme amongst many 
neurodegenerative diseases, therefore maintaining intracellular protein homeostasis 
(proteostasis) by balancing protein folding and misfolding is paramount in protecting the 
functionality of the proteome [133]. Misfolded proteins are generally inactive, but the 
accumulation of these inactive misfolded proteins causes stress responses in cells and 
organelles. The endoplasmic reticulum (ER) is a key organelle in the maintenance of 
proteostasis; ER stress via protein accumulation triggers the unfolded protein response 
(UPR). The UPR promotes correct protein folding and diminishes ER protein level by 
proteosomal degradation, translation mitigation and autophagy [134]. Autophagy plays an 
essential role in proteostasis because of its ability to degrade protein aggregates that cannot 
be processed by the proteasome [135]. Indeed, the autophagosome can break down and 
recycle whole organelles in an effort to promote cell survival. Protein degradation by 




[4]. Ubiquitination along with other covalent attachments such as phosphorylation, 
SUMOylation, and oxidation regulate normal proteome function. Post-Translational 
Modifications (PTMs) of proteins have been shown to facilitate aggregation in many 
neurodegenerative diseases (NDs) [136].  
A hallmark of NDs is the toxic accumulation and proteotoxicity of disease-
associated proteins. Protein accumulation can lead to aggregates or inclusions, which may 
be toxic or protective [137]. Proteotoxicity is especially problematic with respect to post-
mitotic neurons, drawing a clear line between neurodegeneration and age. Mitochondrial 
proteostasis is also critical for cell survival. Its dysfunction can lead to accumulation of 
reactive oxygen species (ROS), which can be disruptive to cellular proteostasis. ROS can 
debilitate cellular processes by damaging DNA, RNA, lipids, and proteins; stress that 
disturbs mitochondrial proteostasis may lead to the irreversible induction of apoptosis. 
Apoptosis, a highly regulated set of pathways leading to cell death, is initiated in cells 
under stress to avoid the damaging of adjacent cells; this, while advantageous to organisms 
in most cases, is detrimental to the nervous system as differentiated neurons cannot be 
reproduced. Although neuronal loss cannot be fully attributed to apoptosis, it is a common 
culprit in many neurodegenerative disorders such as PD, AD, HD and ALS. 
In this review, we describe important factors that can alter proteostasis and how 






Aim of paper 
 
To highlight the many factors that contribute to neurodegeneration such as post-
translational modifications, protein aggregation, ER-stress, and autophagy. The review 
further aimed at describing how alterations in cellular proteostasis can lead to neuronal cell 
death, and highlight the correlation between many neurodegenerative disorders. 
 
 
Figure 1.2 Altered proteostatic levels and protein conformations lead to hallmark 
pathological neurodegenerative pathways. Damaged and excessive protein directly causes 
ER stress and aggregation as well as mitochondrial dysfunction and oxidative stress 




proteins propagating ER stress and mitochondrial dysfunction leading to loss of 
functionality further altering proteostasis. The cellular defense response to these pathways 




Figure 2.2 Pathway of protein throughout the ER. Protein is synthesized in the rough ER 
by ribosomes. Native protein is predominantly exported, while some can aggregate. 
Misfolded protein aggregates are sent to proteasome for degradation. Misfolded protein 
and aggregates promote the UPR,which includes UPR associated gene regulation, ERAD 











Figure 3.2 Neurodegenerative disorders alter specific steps in the autophagic pathway, 
which ultimately leads to neuronal cell death. The altered steps include reduced induction 
levels due to protein aggregation and defective mTOR inhibition; Defects in cargo 
recognition resulting in accumulation of toxic proteins; Mutation in VCP leads to 
inhibited transport of autophagic vesicle in ALS; Defects in lysosome/autophagasome 
fusion and acidification. All defective steps, leading to impairment of protein degradation 
by lysosomal degradation, ultimately leads to the release of cathepsin’s and apoptosis. 
Huntington’s disease (HD); Alzheimer’s disease 
(AD); Parkinson’s disease (PD); spino-cerebelar ataxia (SCA); spino-muscular atrophy 
(SMA); dementia with Lewy bodies (DLB); Amyotrophic Lateral Sclerosis (ALS); 






Effects of SNCA and disease-causing mutations on the proteome of SH-SY5Y 
cells 
SNCA aggregation and accumulation is a key part of PD pathology. It is however 
unknown at what stage SNCA changes its fate and translocates to Lewy bodies. The 
pathogenic mutations (A30P, E46K and A53T), in addition to duplication and triplication 
events, make it worthwhile exploring what effect the expression of these pathogenic 
forms of SNCA has on the proteome in dopaminergic neuronal SH-SY5Y cells. To this 
end we have transfected pcDNA4 empty vector, and the pcDNA4 vector, containing 
SNCA WT, SNCA A30P, SNCA E46K and SNCA A53T into SH-SY5Y cells. Stable cell 
lines were selected by supplementing full media with zeocin. At this stage we have 
extracted total protein from all the clones for 2D-gPAGE analysis and Western blot gels 
have already been run and analyzed. The manuscript is ready for submission to Journal 
of Neuroscience Research.  
 
Contributions: 
I worked with Rashed Abdullah on this project. I performed mammalian cell culture 
maintenance, I performed western blot analysis for multiple replicates as well as control 










Figure 1.3 Whole cells lysate results of transfections of pathological variants of SNCA as 
well as wt-SNCA to mimic duplication/triplication event. Cells were transfected with 
pcDNA3 as a transfection control; wt-SNCA to mimic a duplication/triplication event; 
A30P-SNCA, E46K-SNCA, and A53T-SNCA to mimic the presence of the pathological form 




Western blot images are representative blots. a) Whole cells lysate of transfections of 
pathological mutations under no treatments, H2O2, and L-Dopa treatments (n=3). b) An 
assay of cell viability as measured by the neutral red assay. Cells were checked to determine 
if the viability was affected by transfections of pathological mutants and by H2O2 and L-
Dopa treatments (n=3). We found no significant decrease in the viability of cell treated 
with H2O2, and L-Dopa. 
 
 
Alpha-Synuclein Multimerization is Dependent on Structural Characteristics 
of Repeated KTKEGV Regions 
 
 
A physio-pathological hallmark of PD is the presence of Lewy Bodies: aggregates which 
are highly enriched in -syn. -syn is an intrinsically disordered protein that forms 
soluble multimers, which may or may not contribute to its aggregation. Isolating critical 
components of alpha-synuclein’s structure could lead to a therapeutic strategy of 
preventing its aggregation. The repeated KTKEGV motif has been implicated as critical 
to neurotoxicity and the presence of multimers or exclusive presence of monomers in 
neuroblastoma cells. Targeting the repeated motif. KTKEGV, is a sensible approach to 
studying the critical components of -syn proteostasis simply due to its prevalence 
throughout the protein. We transfected BE(2)-M17 human neuroblastoma cells in order to 
overexpress at similar levels alpha-synuclein containing mutations in the KTKEGV 
motif. Western blotting was used to measure -syn multimeric distributions in whole cell 




neurons is cell-type specific and influenced by the sequence of repeated N-terminus 




I worked closely with Benjamin Rosen. I assisted with subcellular fractionations of 
BE(2)-M17 cells, cell culture maintenance, and western blot analysis. I worked on 






This study aims to both clarify the importance of the repeats sequence to alpha-synuclein 
multimerization and aggregation in neurons as well as within subcellular compartments 
















Figure 1.4 Subcellular fraction comparison of alpha-synuclein in M17D cells stably 
overexpressing repeat mutant SNCA. (A, D) Cytosolic (B, E Membrane bound (C, F, I) 






Review Project: The Intersection of Parkinson’s disease, viral 
infections and COVID-19 
 
The novel SARS-CoV-2 coronavirus (COVID-19) pandemic has caused a global health 
crisis infecting millions worldwide. Along with flu-like symptoms (fever, chills, cough) a 
large number of infected individuals also experience a host of neurological issues 
including loss of smell and taste, dizziness, decreased alertness, and brain inflammation. 
A striking number of symptoms including gut issues are also prevalent in PD. A higher 
mortality rate has also been reported in patients with PD not only due to low age, but also 
through interactions with the brain dopaminergic system and the inflammatory response. 
The gut microbiota plays an important role in many processes outside of a healthy 
digestive system. It has been shown to be essential in protecting against host pathogens 
[138] and even plays a role in our psychological well-being [139]. Viral infections are 
among some of the most common pathogens invading our gut microbiome causing 
dysbiosis and a multitude of Gastrointestinal issues (GI)[140]. Patients with PD display 
an array of GI complications such as constipation, dysphasia, and dysbiosis (Table) [141] 
and these complications often occur years before hallmark motor symptoms arise [142]. 
The gut microbiota is also decreased in older adults due to a number of factors that 
include diet, genetics, and environmental factors [143]. It has also been noted that severe 
viral infections could possibly increase the risk of developing PD later in life [144] 
although not the primary cause but merely a risk factor. Evidence has suggested that 
SARS-CoV-2 RNA can be detected in the stool of some patients with COVID-19 [145]. 




severity, particularly as the higher COVID-19 mortality rate is seen within the elderly 
population that already have a decreased microbiota. This may also suggest an increased 
chance of COVID-19 mortality for a patient with PD due to an increase of underlying 
conditions which include a compromised Gut flora [146]. Revised manuscript 
resubmitted to Molecular Neurobiology. 
 
Concluding remarks 
In this review we have highlighted the intersections between PD, viral infections and 
COVID-19 with the emphasis on the many similarities between RNA viral pathways and 
neurodegeneration in PD. Indeed, the onset and progression of PD, as detailed in the 
Braak hypothesis, as well as the pathogenic nature, molecular mechanisms, and symptom 
development of the disorder share many similarities with the SARS-CoV-2 virus and 
COVID-19. As further research is conducted, more evidence of a possible correlation 
between PD, Viral infections and the current SARS-CoV-2 virus will become available. 
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Fig. 1.5 The Brain-Gut microbiota axis: Schematic diagram highlighting the relationship 
between the brain and gut microbiota. A rich and diverse microflora allows for healthy 
immune and regulatory mediators, whereby a compromised gut microflora caused by 
viral infections, stress, and poor diet can cause a pro-inflammatory state with implications 
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Appendix A: List of Vectors 
 
 
Vector Maps were obtained from manufacturer’s website. 
 







































Appendix B: Molecular size markers 
 




B-2. Hi-Lo DNA Marker  
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